28/10/2013
PET tracer shows potential in understanding CNS drug resistance
C-11 laniquidar appears to be safe for PET imaging and might prove effective for use as a biomarker for expression of multidrug transporters such as P-glycoprotein in the brain, which could shed light on resistance to central nervous system drugs such as those used to treat epilepsy. In the study, six patients underwent 10 sequential whole-body PET scans, and results showed low uptake of the agent in the brain and high uptake in the liver, spleen, kidneys and lungs. The results published in the Journal of Nuclear Medicine indicate C-11 laniquidar is safe for PET imaging, with a total dose of about 2 mSv for a neurological PET/CT test.
For more information visit www.smartbrief.com or www.molecularimaging.net